SKU: DHC266 | Last Updated On: 2019-08-13 | No. of Pages: 206 | Available Formats
SKU: DHC266 | Published On: 2019-08-13 | No. of Pages: 206 | Available Formats
The global Cough Suppressant Drugs market is expected to grow at a CAGR of XX% to reach a market value of USD XX million by 2026.
A cough is a reflex action to clear your airways of mucus and irritants such as dust or smoke. A cough is the most common symptom of various upper and lower respiratory tract infections. It affects a large proportion of the population leading them to seek medical attention. Cough Suppressant, also known as Antitussives, are widely used to relieve the symptoms of cough. They are substances which suppress the coughing itself.
The global market for the Cough Suppressant Drugs Market is primarily driven high prevalence of cough. Moreover, cough can be contagious and gets transmitted through bacteria and viruses to the unaffected people and is expected to increase the demand for cough suppressant drugs.
However, stringent regulations against the use of cough suppressant are expected to hinder the market progress.
By Drug type, the global cough suppressant drugs market is segmented into dextromethorphan, codeine, noscapine, butamirate, benzonatate, pholcodine, and others. Codeine and Dextromethorphan are the most common and widely used cough suppressant in the market. However, the changing of safety labels to prevent addiction to Codeine may hinder its market. For instance, in January 2018, the U.S. FDA made safety label changes to limit the use of prescription containing codeine in cough and cold medicines for children younger than 18 years. Consequently, these products will no longer be prescribed for the pediatric population in the treatment of cough. February 2018, the Therapeutic Goods Administration in Australia, relabeled codeine as prescription only medicine as regular use of codeine-containing medications may lead to its addiction. Previously, it was available as an over-the-counter medication.
By dosage form, the global cough suppressant drugs market is segmented into syrup, tablet, and others. Syrup segment holds the most significant market share is owing it to its quick relief. However, the tablet share is fast growing attributing to the recent new drug releases.
By age group, the global cough suppressant drugs market is segmented into pediatric and adult. Adult share holds the most significant segment was owing to restrictions on medication which can be prescribed to the pediatric population.
North America is the dominant share in the global Cough Suppressant Drugs market, and it is primarily attributed to factors such as various approvals to novel drugs by the FDA. Moreover, its broad base of the patient population and the established healthcare infrastructure and the rising disposable income and higher investment in R&D activities contribute to the growth of North America’s share.
Key players are adopting strategies such as mergers and acquisitions, partnerships, and regional expansion to stand out as strong competitors in the market. New product launches along with increased focus on R&D are other ways the leading players improve their market presence.
December 2018, Aytu BioScience, a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, announced the commercial availability of Tuzistra XR (codeine polistirex and chlorpheniramine polistirex) oral suspension, CIII. and has now shipped initial Tuzistra XR product supply to U.S. wholesalers for availability to retail pharmacies throughout the U.S.
November 2018, Aytu BioScience, entered an exclusive license with Tris Pharma for FDA-approved Tuzistra XR. Aytu BioScience also licensed complementary antitussive product with pending FDA approval.
March 2018, Perrigo Company received FDA approval for Mucinex DM Maximum Strength, which is indicated to control coughs and break up mucus.
2015, Vernalis and Tris Pharma received the U.S.FDA approval for the New Drug Application (NDA) for Tuzistra XR. The Tuzistra XR is a codeine-based extended-release oral suspension for cough-cold treatment.
2015, Tris Pharma, Inc. entered into a license, supply, and distribution agreement with Pfizer Consumer Healthcare (a part of Pfizer Inc.). According to the agreement, Pfizer Consumer Healthcare will commercialize Tris’ extended release dextromethorphan cough syrup under the Robitussin Brand.
Why Purchase the Report?